Company intelligence / Profile preview

Tigris Pharmaceuticals, Inc.

Bonita Springs, Florida, USA

Ownership: Private
Development stage: Other

Overview

Tigris Pharmaceuticals developed novel small molecule therapeutics for oncology. Its lead program, AFP464 (aminoflavone prodrug), targeted the p53 pathway and entered Phase I/II trials for triple negative breast cancer but was ultimately discontinued. Another agent, GGTI-2418, also reached early clinical development. No active pipeline remains as of the most recent information.

Therapeutic areas: Oncology
Modalities: Small molecules/prodrugs
Industry: Biotech

Drug pipeline

2 assets

aminoflavone

1 more asset in the full pipeline.

Partnerships

Collaborated with academic centers such as University of Pennsylvania and Indiana University Melvin and Bren Simon Cancer Center for clinical studies on GGTI‑2418

Beyond the preview

Go deeper on Tigris Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tigris Pharmaceuticals, Inc..